PMID- 18536317 OWN - NLM STAT- MEDLINE DCOM- 20080729 LR - 20131121 IS - 0301-4894 (Print) IS - 0301-4894 (Linking) VI - 109 IP - 3 DP - 2008 May TI - [Recent advances in treatment of pancreatic neuroendocrine tumors]. PG - 143-6 AB - The recent consensus on the diagnosis and treatment of pancreatic neuroendocrine tumors (PNET) is described. The selective arterial secretagogue injection test and somatostatin receptor scintigraphy are essential for the localization of PNET. A few characteristic clinicopathologic findings of PNET in patients with multiple endocrine neoplasia type 1 (MEN 1) have been elucidated and contributed to improved surgical treatment for these tumors, such as pancreas-preserving total duodenectomy for multiple duodenal gastrinomas in patients with MEN 1 and Zollinger-Ellison syndromes, or distal pancreatectomy for patients with MEN 1 and hypoglycemia. Early diagnosis and early surgical resection of PNET are recommended for complete cure of disease. In liver metastasis of PNET, mass reduction surgery with hepatectomy improves the prognosis of patients, and octreotide LAR has been shown to be useful for reducing complications and inhibiting the growth of tumors. FAU - Imamura, Masayuki AU - Imamura M AD - Kyoto University, Osaka, Japan. LA - jpn PT - English Abstract PT - Journal Article PT - Review PL - Japan TA - Nihon Geka Gakkai Zasshi JT - Nihon Geka Gakkai zasshi JID - 0405405 RN - 0 (Antineoplastic Agents, Hormonal) RN - RWM8CCW8GP (Octreotide) SB - IM MH - Antineoplastic Agents, Hormonal/therapeutic use MH - Diagnostic Imaging MH - Humans MH - Laparoscopy MH - Neuroendocrine Tumors/diagnosis/*therapy MH - Octreotide/therapeutic use MH - Pancreatic Neoplasms/diagnosis/*therapy RF - 18 EDAT- 2008/06/10 09:00 MHDA- 2008/07/30 09:00 CRDT- 2008/06/10 09:00 PHST- 2008/06/10 09:00 [pubmed] PHST- 2008/07/30 09:00 [medline] PHST- 2008/06/10 09:00 [entrez] PST - ppublish SO - Nihon Geka Gakkai Zasshi. 2008 May;109(3):143-6.